247.74

1.44% 3.57

Jazz Pharmaceuticals Plc (JAZZ)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$244.17

Offen:

$244.415

24-Stunden-Volumen:

430.32K

Relative Volume:

0.46

Marktkapitalisierung:

$15.56B

Einnahmen:

$4.44B

Nettoeinkommen (Verlust:

$29.49M

KGV:

-13,464.13

EPS:

-0.0184

Netto-Cashflow:

$1.19B

1W Leistung:

+2.78%

1M Leistung:

+3.82%

6M Leistung:

+46.23%

1J Leistung:

+130.18%

1-Tages-Spanne:

$238.92

$249.19

1-Wochen-Bereich:

$234.36

$249.19

52-Wochen-Spanne:

$105.00

$249.19

Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile

Firmenname

Jazz Pharmaceuticals Plc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

353-1-634-7800

Adresse

FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN

Mitarbeiter

2,890

Twitter

@jazzpharma

Nächster Verdiensttermin

2026-08-04

Neueste SEC-Einreichungen

JAZZ's Discussions on Twitter

Compare JAZZ vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
JAZZ Jazz Pharmaceuticals Plc	247.76	15.29B	4.44B	29.49M	1.19B	-0.0184
VRTX Vertex Pharmaceuticals Inc	523.88	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.87	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.67	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.22	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.59	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-10	Fortgesetzt	Raymond James	Outperform
2026-02-27	Eingeleitet	Barclays	Overweight
2025-11-24	Herabstufung	UBS	Buy → Neutral
2025-07-15	Eingeleitet	Deutsche Bank	Buy
2025-03-07	Hochstufung	UBS	Neutral → Buy
2025-02-26	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2025-02-13	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-12-12	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-06-05	Eingeleitet	Goldman	Buy
2024-01-03	Eingeleitet	Robert W. Baird	Outperform
2023-11-27	Herabstufung	UBS	Buy → Neutral
2023-09-29	Eingeleitet	Raymond James	Mkt Perform
2023-06-12	Fortgesetzt	Wells Fargo	Equal Weight
2022-12-09	Hochstufung	Goldman	Neutral → Buy
2022-06-14	Eingeleitet	UBS	Buy
2022-04-06	Herabstufung	Goldman	Buy → Neutral
2021-11-19	Fortgesetzt	Goldman	Buy
2021-10-07	Fortgesetzt	Jefferies	Buy
2021-10-05	Eingeleitet	Citigroup	Buy
2021-09-23	Eingeleitet	Needham	Buy
2021-05-19	Fortgesetzt	JP Morgan	Overweight
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-02-05	Bestätigt	H.C. Wainwright	Buy
2021-02-03	Hochstufung	Piper Sandler	Neutral → Overweight
2021-01-29	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2020-12-16	Eingeleitet	UBS	Buy
2020-11-03	Bestätigt	H.C. Wainwright	Buy
2020-10-09	Bestätigt	H.C. Wainwright	Buy
2020-09-14	Herabstufung	Goldman	Neutral → Sell
2020-09-14	Fortgesetzt	JP Morgan	Overweight
2020-08-06	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2020-07-28	Hochstufung	Wolfe Research	Peer Perform → Outperform
2020-07-23	Hochstufung	H.C. Wainwright	Neutral → Buy
2020-04-06	Eingeleitet	Jefferies	Buy
2020-03-12	Hochstufung	Bernstein	Mkt Perform → Outperform
2020-01-08	Eingeleitet	Goldman	Neutral
2019-08-21	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-06-11	Eingeleitet	Barclays	Overweight
2019-03-20	Eingeleitet	SunTrust	Buy
2018-12-14	Eingeleitet	Wolfe Research	Peer Perform
2018-11-08	Bestätigt	B. Riley FBR	Buy
2018-08-08	Bestätigt	Stifel	Buy
2018-07-11	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2018-03-23	Bestätigt	H.C. Wainwright	Neutral
2018-03-19	Hochstufung	Morgan Stanley	Equal-Weight → Overweight

Alle ansehen

Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten

09:24 AM

JAZZ Maintains Rating by Truist Securities -- Price Target Lowered to $254 - GuruFocus

09:24 AM

Jul 06, 2026

Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com

Jul 06, 2026

Jazz Pharmaceuticals Holds Steady Near Resistance as Volume Patterns Signal CautionQuality Factor - dars.gov.et

Jul 06, 2026

Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus

Jul 06, 2026

Jul 03, 2026

JAZZJazz Pharmaceuticals plc Options - Finviz

Jul 03, 2026

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) Breakout Keeps Valuation In Focus Following Zepzelca Setback And Ziihera Hopes - simplywall.st

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) EVP reports RSU tax withholding and retains 47,911 shares - Stock Titan

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) CEO shares withheld to cover RSU tax obligations - Stock Titan

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) insider RSU tax withholding detailed - Stock Titan

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) CFO reports 3,343-share tax withholding - Stock Titan

Jul 02, 2026

Jazz Pharmaceuticals (JAZZ) Price Forecast: Will Breakout Confirm Higher Highs? - FXEmpire

Jul 02, 2026

Jazz Pharmaceuticals stock hits all-time high at 243.39 USD - Investing.com

Jul 02, 2026

Jul 01, 2026

Form 144 Jazz Pharmaceuticals Plc For: 1 July By Investing.com - Investing.com Nigeria

Jul 01, 2026

Bruce Cozadd files Form 144 to sell shares — Jazz Pharmaceuticals (NASDAQ: JAZZ) - Stock Titan

Jul 01, 2026

Jun 30, 2026

Enterprise value to revenue forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView

Jun 30, 2026

Price to earnings forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView

Jun 30, 2026

Price to book forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView

Jun 30, 2026

Is Jazz Pharmaceuticals (JAZZ) Using AbCellera Deal to Quietly Redefine Its Oncology Strategy? - simplywall.st

Jun 30, 2026

3 Overrated Stocks Walking a Fine Line - Yahoo Finance UK

Jun 30, 2026

Price to sales forward of Jazz Pharmaceuticals plc – NASDAQ:JAZZ - TradingView

Jun 30, 2026

Jun 29, 2026

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView

Jun 29, 2026

Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks - AOL.com

Jun 29, 2026

Jun 27, 2026

Erica Jefferson Joins Jazz Pharmaceuticals as Chief Communications Officer - hrtoday.in

Jun 27, 2026

Jun 26, 2026

JAZZ Forecast — Price Target — Prediction for 2027 - TradingView

Jun 26, 2026

Jazz Pharmaceuticals' lung cancer drug setback in late-stage trials: Here's why the stock impact may be more limited than it looks - MSN

Jun 26, 2026

Jazz Pharma announces late-stage trial setback for lung cancer therapy - MSN

Jun 26, 2026

Jazz Pharmaceuticals Public Limited Company Actuals & Estimates (NASDAQ:JAZZ) - TradingView

Jun 26, 2026

Jazz Pharmaceuticals: Why It's Time To Cash Out (Rating Downgrade) (NASDAQ:JAZZ) - Seeking Alpha

Jun 26, 2026

Jun 25, 2026

Jazz Pharmaceuticals (JAZZ) Reframed Zepzelca Growth, Is The Stock Still Below Fair Value? - simplywall.st

Jun 25, 2026

Strong Leaders Build Strong Teamsand Strong Teams Change Patients’ LivesJazz Pharmaceuticals - Oncodaily

Jun 25, 2026

Jazz Pharmaceuticals PLC (HAM:J7Z) Stock Price, Trades & News - GuruFocus

Jun 25, 2026

Jun 24, 2026

Jazz Pharmaceuticals (JAZZ) Stock Gets Fair Value Boost As Ziihera Views Split Analysts - Yahoo Finance

Jun 24, 2026

Jun 23, 2026

Jazz Pharmaceuticals and AbCellera Biologics Inc. (ABCL) Announce Collaboration - Yahoo Finance UK

Jun 23, 2026

Will Zepzelca’s Failed LAGOON Trial in Second-Line SCLC Change Jazz Pharmaceuticals' (JAZZ) Narrative? - simplywall.st

Jun 23, 2026

Jun 22, 2026

JAZZ’s Zepzelca fails to meet primary goal in lung cancer study - MSN

Jun 22, 2026

Investor Outlook: Jazz Pharmaceuticals Plc (JAZZ) And Its 14.40% Potential Upside - DirectorsTalk Interviews

Jun 22, 2026